At the news
? BEARISHIMPACT 7/10 PRESS-RELEASE filed May 12, 2026 at 07:30 ET
SAB Biotherapeutics reported Q1 2026 EPS of -$0.35, a 68.3% miss vs consensus of -$0.21, with net loss widening to $18.9M from $5.2M a year ago. The company highlighted continued SAFEGUARD trial enrollment progress, FDA acceptance of C-peptide as a surrogate endpoint for accelerated approval, and a strong $217.6M cash position providing runway through 2028.
- Q1 2026 EPS of -$0.35 missed consensus of -$0.21 by 68.3%
- Net loss widened to $18.9M from $5.2M in Q1 2025
- R&D expenses increased to $13.4M from $7.7M YoY
- Cash position of $217.6M at March 31, 2026, providing runway through 2028
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access